Mortality and Morbidity of Human Metapneumovirus Infection in the Pre-COVID-19 Era: The Value of the Charlson Comorbidity Index on Outcome Prediction.

INTRODUCTION: Human metapneumovirus (HMPV) is an important cause of seasonal respiratory tract infections, mainly in children and immunocompromised adults. The use of the Charlson Comorbidity Index (CCI) to predict outcomes in hospitalized patients has been validated in several settings. OBJECTIVE: This study aims to describe the clinical characteristics of adult patients with HMPV infection and evaluate the value of the CCI in predicting outcomes in patients with acute HMPV infections requiring hospitalization. METHOD: This is a single-center case-series study of hospitalized patients with HMPV infection in 2017. RESULTS: Twenty-two adult patients with a mean age of 65 years were reviewed. The mean CCI was 4.6±2.6. The overall mortality was 22%. An abnormal chest X-ray (CXR) was reported in 15 patients. CCI was not different between survivors and non-survivors. Non-survivors were more likely to have abnormal CXR and a higher fever at the time of diagnosis, required mechanical ventilation, or had other concomitant infections. CONCLUSION: The average CCI was 4.5, which was not significantly different between survivors and non-survivors. The mortality rate was elevated by 22% and was likely associated with admission to the ICU as well as the presence of another concomitant infection.

Prognostic value of initial elevation in cardiac troponin I level in critically ill patients without acute coronary syndrome.

BACKGROUND: Cardiac troponin I levels are often obtained to help rule out acute coronary syndrome. OBJECTIVE: To determine if elevation of troponin level within 24 hours for patients without acute coronary syndrome admitted to the intensive care unit provides important prognostic information. METHODS: Patients without acute coronary syndrome admitted to the intensive care unit were prospectively divided into 2 groups according to highest serum level of cardiac troponin I within 24 hours of admission (elevated > 0.049 ng/mL; control ≤ 0.049 ng/mL). Hospital mortality, incidence of intubation, and other parameters were compared between the 2 groups. RESULTS: Patients with elevated troponin level (n = 40) had higher mortality than did control patients (n = 50) (35% vs 12%; P= .01). Compared with control patients, patients with elevated levels were more likely to be intubated (41% vs 17%; P= .02). CONCLUSION: Critically ill patients without acute coronary syndrome with elevated levels of cardiac troponin I at admission had higher mortality and more intubations than did control patients.

Clinical implications of early mitral regurgitation in patients with reperfused acute myocardial infarction.

BACKGROUND: The mechanisms by which mitral regurgitation (MR) may lead to an adverse prognosis after reperfused acute myocardial infarction (AMI) have not been fully investigated. We hypothesized that in the early phase of ST-elevation AMI, MR may lead to progressive left ventricular (LV) remodeling and subsequent heart failure. METHODS AND RESULTS: A series of 184 patients with AMI successfully treated with primary angioplasty underwent serial two-dimensional echocardiography at admission, at 1 and 6 months, and at 6-month angiography. The mean follow-up was 18 +/- 7 months. On the basis of color Doppler, MR was graded from 0 (none) to 4 (severe). Patients were divided into group 1 (n = 146) with an MR grade of < or = 1 and group 2 (n = 38) with an MR grade of > or = 2. The regurgitant volume and effective regurgitant orifice area of MR were significantly higher in group 2 than in group 1 (36.7 +/- 12.9 mL/beat vs 4.67 +/- 3.2 mL/beat, P < .0001; 22.5 +/- 7.6 mm(2) vs 5.8 +/- 5.7 mm(2), P < .0001, respectively). LV end-diastolic volume progressively increased in group 2 and was significantly higher than in group 1 at 6 months (113.8 +/- 31.8 mL vs 96.9 +/- 34.1 mL, P = .0002), with a higher prevalence of LV remodeling (66% vs 22%, P < .0001). At 2 years, the incidence of heart failure was higher in group 2 than in group 1 (39% vs 12%, P < .0002). A significant correlation was found between effective regurgitant orifice area of MR and baseline to 6-month change of LV end-diastolic volume (P = .001). By stepwise multivariate regression analysis effective regurgitant orifice area of early MR was an independent predictor of LV remodeling (P = .001) and late heart failure (hazard ratio: 1.069, 95% confidence interval 1.033-1.106, P < .0001, Cox analysis). CONCLUSION: In reperfused AMI, early high-degree MR is an important predictor of both LV dilation and subsequent heart failure.

Significance of additional ST segment elevation in patients with no reflow after angioplasty for acute myocardial infarction.

OBJECTIVES: We sought to evaluate the incidence, timing, and clinical significance of additional increase in ST segment elevation (ST-SE) in patients showing no reflow after angioplasty for acute myocardial infarction. METHODS: We studied 26 patients with acute myocardial infarction showing myocardial contrast echocardiography no reflow after successful angioplasty. Baseline and 6-month 2-dimensional echocardiograms were obtained in 21 surviving patients. RESULTS: After angioplasty, 13 patients showed greater than 30% additional increase in ST-SE (group 1), whereas 13 did not (group 2). Baseline clinical, echographic, and angiographic characteristics, and 6-month patency and restenosis rate, were similar between the two groups. From baseline to 6 months, a similar global and regional systolic function was found between the two groups, whereas a higher increase in left ventricular end-diastolic volume occurred in group 1 (135 +/- 45 vs 168 +/- 42 mL, P = .033). The additional increase in ST-SE was not associated with more severe microvascular damage (myocardial contrast echocardiography score index: 0.14 +/- 0.26 vs 0.22 +/- 0.27), higher peak creatine kinase value (4888 +/- 2533 vs 3109 +/- 2055 U/L, P = .061), higher incidence of left ventricular remodeling (73% vs 60%, P = .537), or worse outcome (26 +/- 24 months) such as death (15% vs 23%, P = .619), hospitalization for heart failure (8% vs 23%, P = .277), or reinfarction (8% vs 0%, P = .308). CONCLUSIONS: Our data show that in patients showing no reflow after angioplasty a transient additional increase in ST-SE occurs in half of patients. The prognostic value of additional increase in ST-SE remains uncertain in the era of primary angioplasty.

Predictors of outcome after sirolimus-eluting stent implantation for complex in-stent restenosis.

Few data are available on the effectiveness of sirolimus-eluting stent implantation for the treatment of in-stent restenosis, and no data exist about the predictors of outcome after sirolimus-eluting stent implantation for complex in-stent restenosis (diffuse, proliferative, or total occlusion). From April 2002 to May 2004, 136 patients with 161 complex in-stent restenoses underwent sirolimus-eluting stent implantation. At 9 months, 5 patients had died (3 of cardiac and 2 of noncardiac causes), no reinfarctions had occurred, and 11 target vessel revascularization procedures had been performed. The target vessel revascularization rate was 8%, and the in-segment binary restenosis rate was 17%. The predictors of the risk of recurrence were unstable angina as the clinical presentation of in-stent restenosis, an ostial location of the target lesion, lesion length, and sirolimus-eluting stent diameter < or =2.5 mm.